各位先進、各位會員鈞鑒：

台灣肝臟研究學會(Taiwan Association for the Study of the Liver; TASL) 謹訂於2020年12月12-13日(星期六、日) 假高雄義大醫療財團法人義大癌治療醫院6樓大講堂(高雄市燕巢區義大路21號)舉行。

**『TASL 2020 Annual Meeting & The 2nd TASL-AASLD Joint Symposium & The 2nd TASL-KASL-JSH Joint Symposium』**

**研討會主題：Advances in Hepatology from Hospital to Community**

大會邀請國內外對於肝病研究的學者一起與會討論，演講精彩可期。竭誠歡迎各位先進、各位會員一同參與此盛會。

敬頌

鈞安

大會主席：羅錦河

會 長：林漢傑

**報名資訊:**

1. **線上報名：**

為預先統計人數暨準備參與者相關資料，請於**11月27日**前於線上報名。 12月12日報到當天領取餐券，晚宴憑券入場

(地點: 高雄義大皇家酒店)。

1. **報名網址：**

線上報名連結🡪🡪

1. **晚宴收費**(請事先報名)**：**TASL會員免費，TASL準會員：300元

非TASL會員繳費用$500元。恕不退費，恕不接受現場報名。

1. **繳費方式：TASL準會員及非TASL會員**請於11/27前匯款至下列帳戶並註明匯款人姓名。

※ 請將匯款單影本掃描傳真或Email回傳秘書處，學會確認收到款項後即完成報名程序。

戶名：財團法人台灣肝臟研究暨教育基金會

銀行：合作金庫銀行006（臺大分行）

帳戶：1346765619456

1. **其它相關學分申請中。**

|  |  |  |
| --- | --- | --- |
| 聯絡人：楊紫柔 | 電話: 02-2370-8856 | 傳真: 02-2370-8861 |
| **Email: tasl@tasl.org.tw** | | |

**TASL 2020 Annual Meeting & The 2nd** **TASL-AASLD Joint Symposium**

**&** **The 2nd TASL-KASL-JSH Joint Symposium**

**Theme：Advances in Hepatology from Hospital to Community**

Date: December 12 (Sat.) and 13 (Sun.), 2020

Add: 6F, Auditorium, E-Da Cancer Hospital, E-Da Hospital 義大癌治療醫院6樓大講堂

**December 12(Sat.)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Time** | **Topic** | **Speaker** | **Moderator** |
| 11:45-13:00 | Registration | | |
| 13:00-13:05 | Opening by TASL President | Prof. Han-Chieh Lin 林漢傑 教授 | |
| 13:05-13:10 | Welcome address | Prof. Gin-Ho Lo  羅錦河 副院長或其他義大長官 | |
| **Hepatocellular carcinoma** | | | |
| 13:10-13:30 | Circulating biomarkers for hepatocellular cancer | Prof. Shiou-Hwei Yeh  葉秀慧 教授 | Prof. Pei-Jer Chen  陳培哲 院士 |
| 13:30-13:50 | Recent advances in living-donor transplantation for HCC | Prof. Chih-Che Lin  林志哲 教授 | Prof. Po-Huang Lee  李伯皇 教授 |
| 13:50-14:10 | The new paradigm of systemic treatment for advanced HCC | Prof. Yi-Hsiang Huang  黃怡翔 教授 | Prof. Sheng-Nan Lu  盧勝男 教授 |
| **Liver fibrosis** | | | |
| 14:10-14:30 | How to stop liver fibrosis from progression? | Prof. Ming-Ling Chang  張明鈴 教授 | Prof. Rong-Nan Chien  簡榮南 教授 |
| 14:30-14:55 | Non‐invasive assessments for liver fibrosis & gastroesophageal varices | Prof. Grace Wong  黃麗虹 教授 (CUHK) | Prof. Gin-Ho Lo  羅錦河 教授 |
| 14:55-15:05 | Coffee break | | |
| **Alcoholic and Non-alcoholic Fatty Liver disease** | | | |
| 15:05-15:25 | Updates in the management of alcoholic hepatitis | Dr. Chih-Wen Lin  林志文 副教授 | Prof. Cheng-Yuan Peng彭成元 教授 |
| 15:25-15:50 | The concept and implication of metabolic dysfunction associated fatty liver disease | Prof. Jacob George  (Sydney University) | Prof. Jaw-Ching Wu  吳肇卿 教授 |
| **Chairman lecture and research award presentation** | | | |
| 15:50-16:10 | Chairman lecture  (Chairman of TASL 2020 annual meeting) | Prof. Gin-Ho Lo  羅錦河 教授 | Prof. Shou-Dong Lee  李壽東 教授 |
| 16:10-16:30 | Research award presentation | | Prof. Chia-Ming Chu  朱嘉明 教授 |
| 16:35-17:35 | Satellite symposium (I) | 癌醫-6樓 大講堂 | BMS/BMS+ONO |
| 17:35-18:20 | Satellite symposium (II) | 癌醫-6樓 大講堂 | Bayer |
| 17:35-18:20 | Satellite symposium (III) | 義大-6樓 大講堂 | Roche |
| 19:00-21:00 | Gala Dinner (For Registered TASL Members and invited Guests) | | |

**ASL 2020 Annual Meeting & The 2nd** **TASL-AASLD Joint Symposium**

**&** **The 2nd TASL-KASL-JSH Joint Symposium**

**Theme：Advances in Hepatology from Hospital to Community**

Date: December 12 (Sat.) and 13 (Sun.), 2020

Add: 6F, Auditorium, E-Da Cancer Hospital, E-Da Hospital 義大癌治療醫院6樓大講堂

**December 13(Sun.)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Time** | **Topic** | **Speaker** | **Moderator** |
| **07:30-08:20** | **TASL SIG-immunology meeting 義大-6樓 大講堂** | | |
| **The 2nd TASL-AASLD Joint Symposium** 癌醫-6樓 大講堂 | | | |
| 08:30-08:35 | Opening | TASL: Prof. Han-Chieh Lin | |
| 08:35-08:55 | Trends of NASH-HCC risk in US | AASLD:  Prof. Hashem El-Serag | Prof. Han-Chieh Lin |
| 08:55-09:15 | Trends of HBV-HCC risk after NUCs treatment in US | AASLD:  Prof. Anna Suk-Fong Lok | TASL:  Prof. Jia-Horng Kao |
| 09:15-09:35 | Trends of HCV-HCC risk after DAAs treatment in US | AASLD:  Prof. Amit Singal |
| 09:35-09:55 | Trends of HBV-HCC risk after NUCs treatment in Taiwan | TASL:  Prof. Tsung-Hui Hu | TASL:  Prof. Rong-Nan Chien |
| 09:55-10:15 | Trends of HCV-HCC risk after DAAs treatment in Taiwan | TASL:  Dr. Chen-Hua Liu | TASL:  Prof. Chun-Jen Liu |
| 10:15-10:35 | Trends of NASH-HCC risk in Taiwan | TASL:  Prof. Jee-Fu Huang | TASL:  Prof. Ming-Lung Yu |
| 10:35-10:55 | Evolution of Treatment in Advanced HCC | AASLD:  Prof. Josep Llovet | TASL:  Prof. Yi-Hsiang Huang |
| 10:55-11:15 | HCC Debrief from 2020 AASLD The Liver Meeting | AASLD:  Prof. Denise Harnois |
| 11:15-11:30 | Panel Discussion | Prof. Jia-Horng Kao | |
| 11:30-12:15 | Satellite symposium (I)- HCV | 癌醫-6樓 大講堂 | Gilead Sciences |
| 12:15-13:00 | Satellite symposium (II) | 癌醫-6樓 大講堂 | MSD+ Eisai |
| 12:15-13:00 | Satellite symposium (III) | 義大-6樓 大講堂 | Sysmex |
| 13:00-13:45 | Satellite symposium (IV) | 癌醫-6樓 大講堂 | Abbvie |
| 13:00-13:45 | Satellite symposium (V) -HBV | 義大-6樓 大講堂 | Gilead Sciences |

**ASL 2020 Annual Meeting & The 2nd** **TASL-AASLD Joint Symposium**

**& The 2nd** **TASL-KASL-JSH Joint Symposium**

**Theme：Advances in Hepatology from Hospital to Community**

Date: December 12 (Sat.) and 13 (Sun.), 2020

Add: 6F, Auditorium, E-Da Cancer Hospital, E-Da Hospital 義大癌治療醫院6樓大講堂

|  |  |  |  |
| --- | --- | --- | --- |
| **Chronic viral hepatitis** | | | |
| 13:50-14:10 | Current status & future perspective toward a HCV-free country | Prof. Ming-Lung Yu  余明隆 教授 | Prof. Wan-Long Chuang莊萬龍 教授 |
| 14:10-14:30 | Is antiviral therapy for HCV warranted in all patients with HCC? | Dr. Hung-Chih Yang  楊宏志 副教授 | Prof. Chun-Jen Liu  劉俊人 教授 |
| 14:30- 14:50 | When to start anti-HBV treatment? Therapeutic indications revisited | Dr. Yao-Chun Hsu  許耀峻 副教授 | Prof. Huey-Ling Chen陳慧玲 教授 |
| 14:50-15:10 | To stop or not to? Pros and cons of a finite oral anti-HBV therapy | Dr. Wen-Juei Jeng  鄭文睿 副教授 | Prof. Chau-Ting Yeh  葉昭廷 教授 |
| 15:10-15:20 | Coffee break | | |
| **The 2nd TASL KASL JSH Joint Symposium** | | | |
| 15:20-15:35 | Unmet needs of HBV treatment in Japan  (Q&A) | JSH:  Prof. Yasuhito Tanaka | Prof. Tetsuo Takehara Director General,  JSH |
| 15:35-15:50 | Unmet needs of HBV treatment in Korea  (Q&A) | KASL:  Prof. Jeong-Hoon Lee | Prof. Han Chu Lee, the President of KASL |
| 15:50-16:05 | Unmet needs of HBV treatment in Taiwan (Q&A) | TASL:  Dr. I-Cheng Lee | Prof. Han-Chieh Lin  President of TASL |
| 16:05-16:20 | Special lecture: Novel treatments for advanced HCC (Q&A) | JSH:  Prof. Masatoshi Kudo | TASL  Prof. Ting-Tsung Chang |
| 16:20-16:25 | Closing remarks | Prof. Han-Chieh Lin  林漢傑教授 | |

**December 13(Sun.)**